Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
THE NMDA RECEPTOR ANTAGONISTS, LY274614 AND MK-801, AND THE NITRIC-OXIDE SYNTHASE INHIBITOR, NG-NITRO-L-ARGININE, ATTENUATE ANALGESIC TOLERANCE TO THE MU-OPIOID MORPHINE BUT NOT TO KAPPA-OPIOIDS
Autore:
ELLIOTT K; MINAMI N; KOLESNIKOV YA; PASTERNAK GW; INTURRISI CE;
Indirizzi:
CORNELL UNIV,COLL MED,DEPT PHARMACOL,ROOM LC524,1300 YORK AVE NEW YORK NY 10021 CORNELL UNIV,COLL MED,DEPT NEUROL & NEUROSCI NEW YORK NY 10021 MEM SLOAN KETTERING CANC CTR,COTZIAS LAB NEUROONCOL NEW YORK NY 10021
Titolo Testata:
Pain
fascicolo: 1, volume: 56, anno: 1994,
pagine: 69 - 75
SICI:
0304-3959(1994)56:1<69:TNRALA>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
ANTINOCICEPTIVE AGENTS; NEURONAL MESSENGER; CALCIUM; RAT; POTENTIATION; ACTIVATION; MECHANISMS; INFUSION; RELEASE; POTENCY;
Keywords:
OPIOID TOLERANCE; MU-AGONIST; KAPPA(1)-AGONIST; KAPPA(3)-AGONIST; MORPHINE; U50488H; NALOXONE BENZOYLHYDRAZONE; NMDA RECEPTOR ANTAGONIST; MK-801; LY274614; NITRIC OXIDE SYNTHASE INHIBITOR; NG-NITRO-L-ARGININE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
33
Recensione:
Indirizzi per estratti:
Citazione:
K. Elliott et al., "THE NMDA RECEPTOR ANTAGONISTS, LY274614 AND MK-801, AND THE NITRIC-OXIDE SYNTHASE INHIBITOR, NG-NITRO-L-ARGININE, ATTENUATE ANALGESIC TOLERANCE TO THE MU-OPIOID MORPHINE BUT NOT TO KAPPA-OPIOIDS", Pain, 56(1), 1994, pp. 69-75

Abstract

Once daily s.c. administration of 5 mg/kg morphine, a mu-opioid agonist, or U50488H (U50),:a kappa(1)-opioid agonist, for 5 days in male CD-1 mice results in a 2-3-fold shift to the right of the respective analgesic (tail flick) dose-response curves, indicating the development of tolerance. Concurrent s.c. administration of the competitive NMDA receptor antagonist, LY274614 (LY), at 24 mg/kg/24 h infusion (osmotic pump) or 6 mg/kg i.p. once daily attenuates the development of morphinetolerance, when the response to saline plus morphine, is compared on day 5 with LY plus morphine. Using this paradigm, once daily administration of either the non-competitive NMDA antagonist, MK-801, at 0.3 mg/kg i.p. or the nitric oxide synthase inhibitor, NG-nitro-L-arginine (NorArg), at 1 mg/kg i.p. twice daily attenuated the development of morphine tolerance. None of these drugs modify the tail-flick response oralter the ED(50) for morphine. In contrast, co-administration of LY, MK-801 or NorArg, as above, failed to attenuate the development of tolerance to U50 or to the kappa(3)-opioid agonist, naloxone benzoylhydrazone (NalBzoH). These results suggest that mu-opioid tolerance but notkappa(1)- or kappa(3)-opioid tolerance involves the mediation of NMDAreceptors and the nitric oxide system.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/07/20 alle ore 12:02:55